FDA Grants Priority Review for Imfinzi in MIBC Treatment
FDA grants Priority Review for Imfinzi to treat muscle-invasive bladder cancer based on NIAGARA trial.
AstraZeneca's supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) has been accepted and granted Priority Review by the U.S. FDA for treating muscle-invasive bladder cancer (MIBC). This designation reflects the therapy's potential to improve patient outcomes in a challenging setting where existing treatments often lead to recurrence or poor prognosis.
The application is supported by Phase III NIAGARA trial data showing that Imfinzi, combined with neoadjuvant chemotherapy and followed by adjuvant monotherapy, reduced disease progression risks by 32% and improved survival rates. Regulatory decisions are anticipated in mid-2025.
Reporting on the science, business and regulation shaping the pharmaceutical industry.
Altro da Pharma News
Tutti gli articoli →
Medicus Pharma presenta all’FDA il protocollo di fase 2b/3 per Teverelix
Fresenius Kabi Riceve una Lettera di Richiamo dalla FDA dopo Fallimenti nelle Indagini sul Processo Asettico presso lo Stabilimento di Melrose Park
Discussion